retatrutide clinical trials phase 3 New GLP-3 drug significantly slashes both weight and blood sugar levels in III trial Interesting data from the @EliLillyandCo

Effect of betaine on reducing body fata systematic review and meta-analysis of randomized controlled trials

Smith DB, Johnson KS: Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase

Safety, side effects, and clinical oversight The FDA-labeled side-effect profile for GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common

According to a study by Winther et al., higher concentrations of plasma TMAO were related to mortality, CVDs, and poor renal outcome in patients with type 1 diabetes (137)